

## UNITED STATES DE ARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

e e tour

SERIAL NUMBER	FILING DA	TE	
08/477,3	16 06	/07/95	GRAY

J ORNEY DOCKET NO. 028723-060

18M2/010%

R DANNY HUNTINGTON BURNS DOANE SWECKER & MATHIS PO BOX 1404 ALEXANDRIA VA 22313-1404

EXAMINER				
MARSCHEL, A				
ART !WIT	PAPER NUMBER			
1807	12			
DATE NAL :C:	01/08/98			

Below is a communication from the EXAMINER in charge of this application COMMISSIONER OF PATENTS AND TRADEMARKS

## ADVISORY ACTION

		ADVICON ACTION			
_ THE	PERIOD FOR RESPONSE:				
a) 🔲 i	is extended to run	or continues to run	from the date of the final rejection		
b) 🗌	expires three months from the date of the event however, will the statutory period	ne final rejection or as of the mailing dat for the response expire later than six m	te of this Advisory Action, whichever is later. In no conths from the date of the final rejection.		
	The date on which the response, the per	tition, and the fee have been filed is the xtension and the corresponding amoun	(a), the proposed response and the appropriate fee. e date of the response and also the date for the t of the fee. Any extension fee pursuant to 37 CFR riod for response or as set forth in b) above.		
Арр	ellant's Brief is due in accordance with	37 CFR 1.192(a).			
App to p	licant's response to the final rejection, fil lace the application in condition for allov		idered with the following effect, but it is not deemed		
1. 🗹	The proposed amendments to the claim	and /or specification will not be entered	and the final rejection stands because:		
	<ul> <li>There is no convincing showing upresented.</li> </ul>	nder 37 CFR 1.116(b) why the propose	d amendment is necessary and was not earlier		
	b. 🔀 They raise new issues that would	require further consideration and/or sea	arch. (See Note).		
	c. They raise the issue of new matter. (See Note).				
	d. They are not deemed to place the appeal.	e application in better form for appeal b	by materially reducing or simplifying the issues for		
	e. 🔀 They present additional claims w	thout cancelling a corresponding numb	er of finally rejected claims.		
	NOTE: The proposed clm about 40 KB as a these issue would	re add the new issue refuse further cornder	of a probe completely of interplace tanget miterial.		
2.	Newly proposed or amended claims the non-allowable claims.		submitted in a separately filed amendment cancelling		
3. 🕱	be as follows:	amendment 🗌 will be entered 🔀 w	vill not be entered and the status of the claims will		
	Claims allowed:	<u> </u>			
	Claims objected to:				
	However;				
	Applicant's response has overcom	e the following rejection(s):			
4. 📈	The stildavit, exhibit or request for roof of record that are still See your the attacker for	S Twe insideration has been considered but de applicable due to the about the response,	wes not overcome the rejection because of resson		
5.	The affidavit or exhibit will not be considered.	dered because applicant has not shown	good and sufficent reasons why it was not earlier		
The	proposed drawing correction  has	has not been approved by the exa	aminer.		
Oth	er				
7,316	•				
DTO1 20	2 (DEV 5.89)				

Further Explanation of Item 4 on the attached Advisory Action:

Applicants arguments based on claim amending are moot in overcoming the rejections due to the above discussed non-entry of the amendment, filed 12/9/97.

Other arguments are responded to as follows: The proposed amendment to the word "probes" in proposed amended claim 1, line 3, combined with the explanation in the REMARKS, filed 12/9/97, on page 5 therein would have overcome the rejection based on singular "probe" versus "probes" citation unclarity in the claim. The other 2nd paragraph rejection based on a lack specificity or hybridization condition limitations in the claim would not, however, been overcome because in hybridization probe assays both what is stained or detected versus what is "not" are critical aspects of such assays. omission of any mention of specificity/hybridization conditions in the claim therefore leaves open a critical target discriminatory feature of the invention. It is noted that staining of nucleic acid has been performed in the art to stain most if not all of a chromosome and thus a method of staining may simply require the staining of some minimal chromosomal material as a requirement without necessarily "not" staining some other portion thereof. Thus, the art that may or may not be applicable to be considered in methods as instantly claimed critically must be evaluated regarding what the metes and bounds of the stained material is. Without specifying it clearly in the claims no

amount of discussion in the specification negates this well known breadth to hybridization assay, especially chromosomal staining type methods.

Applicant argue the applicability of Weissman et al. by arguing that chromosomal rearrangement assays are not suggested or motivated therein. Applicants are referred to the office action, mailed 9/4/96, wherein Weissman et al. at column 2, line 13, through column 4, line 5, is pointed to. Specifically, in column 2, lines 16-20, the translocation of marker genes from one chromosomal region to another is described. This is clearly gene rearrangement in contrast to the arguments of applicants. The last argument directed to interphase target material is moot in that this is a new issue and one of the reasons for the non-entry of the amendment, filed 12/9/97. It is acknowledged that Weissman et al. does not contain disclosure of interphase chromosomal target material.

The double-patenting rejections are maintained as not being argued.

This application is subject to the provisions of Public Law 103-465, effective June 8, 1995. Accordingly, since this application has been pending for at least two years as of June 8, 1995, taking into account any reference to an earlier filed application under 35 U.S.C. 120, 121 or 365(c), applicant, under 37 CFR 1.129(a), is entitled to have a first submission entered and considered on the merits if, prior to abandonment, the

submission and the fee set forth in 37 CFR 1.17(r) are filed prior to the filing of an appeal brief under 37 CFR 1.192. Upon the timely filing of a first submission and the appropriate fee for a large entity under 37 CFR 1.17(r), the finality of the previous Office action will be withdrawn. In view of 35 U.S.C. 132, no amendment considered as a result of payment of the fee set forth in 37 CFR 1.17(r) may introduce new matter into the disclosure of the application.

If applicant has filed multiple proposed amendments which, when entered, would conflict with one another, specific instructions for entry or non-entry of each such amendment should be provided upon payment of any fee under 37 CFR 1.17(r).

Papers related to this application may be submitted to Group 1800 by facsimile transmission. Papers should be faxed to Group 1800 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is (703) 305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ardin Marschel, Ph.D., whose telephone number is (703) 308-3894. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

If attempts to reach the examiner by telephone are unseccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

January 6, 1998

ARDIN H. MARSCHEL PRIMARY EXAMINER GROUP 1800